Status:
COMPLETED
Clusterin Level and Polycystic Ovary Syndrome
Lead Sponsor:
Sanliurfa Mehmet Akif Inan Education and Research Hospital
Conditions:
Polycystic Ovary Syndrome
Ovulation Disorder
Eligibility:
FEMALE
18-45 years
Brief Summary
Clusterin, a protein involved in metabolic syndrome, insulin resistance, and metabolic disorders associated with inflammation and oxidative stress such as atherosclerosis, Alzheimer's and some maligna...
Detailed Description
The study included 118 women diagnosed with PCOS according to the Rotterdam criteria and 62 age-matched healthy women without cardiovascular risk factors. The patients diagnosed with PCOS were also cl...
Eligibility Criteria
Inclusion
- Women aged between 18 and 45,
- natural bilateral ovaries and no functional cysts on transvaginal ultrasound.
Exclusion
- who have hyperandrogenism/hyperandrogenemia
- who have non-classical congenital adrenal hyperplasia (17 OHP value \>2 nmol/L)
- who have thyroid disease (TSH \>5 mlU/L),
- women with hyperprolactinemia (Prolactin\>30 mlU/mL)
- patients taking hormonal drugs or ovulation induction agents.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT06601725
Start Date
April 1 2021
End Date
December 1 2021
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nefise Nazlı Yenigül
Bursa, Turkey (Türkiye), 16110